Core Insights - The company reported a 1% organic growth for the third quarter, with Life Sciences remaining flat and Diagnostics experiencing low single-digit growth [1] Revenue Performance - Diagnostics showed better-than-expected performance, driven by strength in newborn screening, while the Immunodiagnostics business faced challenges due to headwinds in China [1] - Life Sciences faced weaker-than-anticipated performance in reagents, but this was offset by growth in instrumentation and software businesses, resulting in an overall flat performance [1]